Published in FDA Law Weekly, December 28th, 2006
Shipment of these products will begin immediately following a 2005 patent litigation settlement with GlaxoSmithKline.
Teva's ondansetron injection products are the AP-rated generic equivalent of GlaxoSmithKline's antiemetic Zofran injection.
The product, in the three...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
Source: FDA Law Weekly (2006-12-28)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.